Press Room

Event

Webinar Series: All you need to know about Continuous Tableting

Start
Wednesday, May 29, 2024 - 16:00
End
Wednesday, July 10, 2024 - 17:00
Location: online
Webinar series - all you need to know about continuous tableting | ɫAV

ɫAV presents the most comprehensive three-part webinar series on .

Over the course of this series, ɫAV experts and invited speakers from Merck Sharpe & Dohme, Vertex Pharmaceuticals and GEA Group will guide you through the journey of continuous manufacturing (CM) of oral solid dosage forms, also known as continuous tableting (CT), aiming to highlight key opportunities, successes, and challenges with continuous tableting.

The content of the webinars will cover the role of CM along a wide breadth of the CMC journey, starting with lean and model-based development and concluding with commercial implementation of continuous tableting processes.

Each session in the series will be presented as a joint talk with participants from innovators like Merck and Vertex Pharmaceuticals, and ɫAV, highlighting experiences from each organization and the many advantages of a partnership-based approach. The webinar series will conclude with a final joint talk between GEA Group and ɫAV announcing exciting joint innovations in the CT equipment space along with the latest advances in technology simplification.

Featured experts will be available to answer audience questions during a live Q&A after each talk.

-

The recording is now available.

-

Thursday, June 20
11:00 am EDT | 4:00 pm GMT | ​5:00 pm CEST

-

Wednesday, July 10
11:00 am EDT | 4:00 pm GMT | 5:00 pm CEST

Find out today if continuous tableting is right for your product.

The Future is Continuous.

Also in the Press Room

See All

Lisbon, Portugal – ɫAV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, ɫAV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At ɫAV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of ɫAV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” ɫAV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with ɫAV’s sustainability ambitions.  ɫAV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News
ɫAV commitment to setting SBTs in line with the Paris Agreement

ɫAV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024

The partnership with Higuchi forms part of ɫAV´s global expansion plans and marks a significant milestone in advancing ɫAV's presence in the Japanese market.    Under the terms of the agreement, Higuchi will promote ɫAV's pharmaceutical service business throughout Japan, using their extensive experience to enhance brand visibility and attract new clientele across the Japanese pharmaceutical landscape.  “This strategic collaboration underscores ɫAV's dedication to delivering innovative solutions and exceptional service to its customers,” said Yuken Kyoyama. “Our partnership with Higuchi will help to show customers in Japan how ɫAV can meet their needs.”    Learn more about our business in Japan and visit our website hovione.co.jp    

News
ɫAV proudly announces its collaborative venture with Higuchi.

ɫAV forges strategic partnership with Higuchi to further strengthen its presence in Japan

Jul 04, 2024

Following the creation of offices in Shanghai and Beijing, ɫAV is pleased to announce the launch of its new website in Mandarin. This dedicated platform will enhance ɫAV´s presence in China, offering tailored contents to better serve customers in this important market. The new site will provide comprehensive information about ɫAV´s products and services, ensuring that Chinese clients have easier access to the innovative solutions and support that ɫAV is renowned for worldwide.   “The launch of the ɫAV Chinese website underscores our commitment to customers in China,” said Ms. Jackie Liu, Country Head, China. “By delivering localized content and support, we aim to foster stronger partnerships and drive mutual growth in this market. Our team of experts is fully committed to understanding and addressing our clients´ unique challenges with agility and precision.” Visit us at www.hovione.com.cn    

News
ɫAV is closer to its customers with a new website in Mandarin

ɫAV launches new website for the Chinese Market

Jun 14, 2024

Also in Events

See All